Premium
IH2 INHIBITION ENHANCES PROTEASOME INHIBITOR RESPONSIVENESS IN HEMATOLOGICAL MALIGNANCIES
Author(s) -
Piva R.,
Bergaggio E.,
Riganti C.,
Vitale N.,
Garaffo G.,
Mereu E.,
Bandini C.,
Pellegrino E.,
Pullano V.,
Labrador M.,
Bertoni F.,
Deaglio S.,
Neri A.,
Palumbo A.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.200_2631
Subject(s) - carfilzomib , cancer research , nicotinamide phosphoribosyltransferase , proteasome inhibitor , idh2 , bone marrow , pharmacology , medicine , biology , multiple myeloma , immunology , nad+ kinase , biochemistry , idh1 , enzyme , gene , mutation
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom